Orphan Drugs Are Safe Niche, Shire Believes

Shire’s CEO extols the value of the orphan drug business model, which accounts for thirty percent of Shire’s sales (up from five percent three years ago). The apparent value in developing drugs for orphan diseases like ALS has not gone unnoticed by big pharma, with the likes of GlaxoSmithKline and Sanofi-Aventis entering these niche markets.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail